



ADMEDUS

INNOVATIVE HEALTH SOLUTIONS

www.admedus.com

Follow us on    

ADMEDUS
INNOVATIVE HEALTH SOLUTIONS

Disclaimer



This presentation is the property of Admedus Ltd (“Admedus”). No part of this presentation may be reproduced or transmitted in any form or by any means without direct permission in writing from Admedus. This presentation is not and does not constitute an offer, invitation or recommendation to subscribe for, or purchase any security and neither this presentation nor anything contained in it shall form the basis of any contract or commitment.

This presentation does not constitute an offer, solicitation or invitation in any, state or jurisdiction anywhere, or to any person to whom, such an offer or sale would be unlawful. This presentation is not intended as an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the United States or to any person to whom it is unlawful to make such an offer, invitation or solicitation. Reliance should not be placed on the information or opinions contained in this presentation. This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. Any decision to purchase or subscribe for securities in Admedus must be made solely on the basis of the information contained in the public domain and if necessary after seeking appropriate financial and legal advice.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, Admedus and its affiliates and related bodies corporate, and their respective officers, directors, employees and agents disclaim any liability (including, without limitation, any liabilities arising from fault or negligence) for any loss arising from any use of this presentation (or its content) or otherwise arising in connection with it. Admedus’ forward-looking statements, intentions, forecasts, prospects, returns, expectations, statements in relation to future matters or other forward looking statement contained in this presentation may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. They are based on a number of estimates, assumptions that are subject to business, scientific, economic and competitive uncertainties and contingencies, with respect to future business decisions, which are subject to change and, in many cases, are outside the control of Admedus and its directors. Neither Admedus nor its directors give any assurance that the forecast performance in the forecasts or any forward-looking statement contained in this presentation will be achieved.

2016-17 Financial Update




The Year in Numbers



\$ millions	FY17	FY16		Change
Group revenue	22.3	14.2	↑	58%
Gross profit	10.7	5.1	↑	110%
GM%	48.1%	36.2%	↑	12%pts
Selling, general and administration costs	(25.0)	(33.4)	↓	25%
Other income	3.4	4.7	↓	(28)%
EBITDA loss	(10.8)	(23.6)	↓	54%
Depreciation and amortisation	(1.9)	(1.5)	↑	(20)%
Operating income / (loss) after income tax	(12.7)	(25.1)	↓	50%
Net working capital	6.0	4.1	↑	(46)%
Net working capital % sales	27.0%	29.2%	↓	(2)%pts
Net operating cash outflows	(12.5)	(21.9)	↓	43%

Group Revenue YOY




- Full year sales of \$22.3M up 58% on prior year and \$1.3M (6%) ahead of forecast
- ADAPT® up 30% to \$6.9M
- Infusion up 74% to \$15.5M assisted by nRAH in H1
- F17 sales growth trajectory accelerated
- \$8.1M incremental sales (F17 vs F16) approximately double prior years \$4.1M (F16 vs F15)

ADAPT – accelerating momentum



ADAPT® Sales - A\$'000




- Sales up 30% to \$6.9M
- Margin of 67%, up 48% points, through combination of manufacturing improvement and scale benefits
- Higher sales and improved margins drive gross profit up 368% to \$4.6M
- All regions contributed positively to the result:
 - North America up 35% (40% in constant currency (CCY))
 - Europe up 9% (15% CCY)
 - Emerging Markets up 170%
- New markets – MENA

ADAPT® - \$ millions	FY17	FY16		Change
Segment revenue	6.9	5.3	↑	30.2%
Cost of sales	(2.3)	(4.3)	↓	47.3%
Gross profit	4.6	1.0	↑	368.1%
GM%	67.1%	18.7%	↑	48.4%pts

Infusion – it starts now


Infusion Sales - A\$'000



- Sales up 74% to \$15.5M aided by \$4.5M in capital sales under the nRAH contract
- Underlying sales (ex capital sales) up more than 20%
- Margin of 40%, down 7% points, impacted by the high proportion of nRAH capital sales
- Higher sales on lower average margin drive gross profit up 48% to \$6.1M
- nRAH set to officially open first week of September



INFUSION - \$ millions	FY17	FY16		Change
Segment revenue	15.5	8.9	↑	74.2%
Cost of sales	(9.3)	(4.7)	↑	97.1%
Gross profit	6.1	4.1	↑	48.0%
GM%	39.6%	46.6%	↓	(7.0)%pts

Gross Profit



- Gross profit up 110% or \$5.6M to \$10.7M for year
- Gross margin expanded 12% points, up 33%
- ADAPT® contributed \$3.6M (64%) and Infusion \$2.0M (36%) of improved gross profit
- Margin improvement driven by ADAPT® whose margins grew to 67% from 19% driven by scale benefits and manufacturing improvements


Net loss and operating cash outflows



- Net loss after tax declined 50% to \$12.7M
- Strong underlying business results compensating for lower R&D refunds (\$1.3M) and higher depreciation and amortisation (\$0.4M)


- Operating cash outflows reduced 43% to \$12.5M, behind EBITDA loss that was down 54%, due to incremental working capital of \$1.9M
- Year-end cash balance of \$11.3M, up \$2.5M, impacted favourably by net funds from shares of \$17.1M partially offset by Regen settlement \$2.4M

Net loss after tax




Divisional contribution


GROSS PROFIT




REVENUE



SG&A evolution as % of revenue




SGA %: gross profit




\$A '000


YOY growth: GP, revenue, SG&A



4 YR CAGR – pre Code Red




5-2 year post Code Red CAGR




Code Red impact on CAGR




Pre Code Red




Post Code Red



5 year CAGR comparison




Profit outgrowing costs – efficiency was key focus of Code Red



The moving parts

ADMEDUS
INNOVATIVE HEALTH SOLUTIONS



Region US



Key Enablers of Performance (past & future)


- Continued optimization of US field force
- Refinement of market potential and targeting by key account
- Launched 1st global marketing campaign
 - Designed by award winning global agency
 - Showcases Clinical superiority of ADAPT

ADAPT 200% growth July 16 vs. July 17

- *CardioCel Neo* growing steadily – up **276%** MTD August since January
- *VascuCel* growing rapidly following initial period of establishing access – **25.4%** compounded monthly growth rate January to August CY17

National Accounts Strategy - plan in place and starting to bear fruit


- Major system signed with sales commencing September 2017
- Currently participating in two tenders worth \$7.8 million over 3 years, commencing H2 2018
- Preparing two additional tender submissions for \$1.8 million award commencing Q1 & Q2 2018, respectively



Region Europe



Significant Upside Potential
Key Markets (DE,UK,FR)
underpenetrated at 58% total business
versus Market at 72%*




ADAPT growth of 9% slightly behind market

- **UK** modest growth at 6% July 16 vs July 17
- **France** growth of **186%** significantly above market (new access)
- **Germany** (-7%) significantly below market
- **RoR** in line with market growth of 12%

Key Enablers of Performance (past & future)

- Restructured largest market, Germany, and recruited new sales force
 - Experienced, clinically adept professionals
 - Concentration of activity in key centers
- Submitted dossier to harmonize the ADAPT portfolio
 - Expand access to total cardiovascular and soft tissue repair market
 - Total market growing at **12.1% CAGR** to 2022
- Launch of global marketing campaign Q4 2017



Region Emerging Markets



Represents Access to growing multi Billion USD Market



- Regional Partner – **Genpharm** driving phased approach ADAPT portfolio launch
- **Phase 1** – In-market and generating revenue KOS, Kuwait, Lebanon, Qatar
- **Phase 2** – In-process – Egypt, Jordan, Iraq, Iran, Bahrain, Oman (entry 2018)

PRIORITY TARGETS (2017-2020)

- MENA
- INDIA
- CHINA



- Exclusive distribution partner secured - **Syncronei Medical**
- Regulatory application submitted July - approval expected in Q4 2017
- Target sites and KOLS secured to support commercial launch 1st revenue expected Q1 2018
- Major launch activity to coincide with the IACTS Annual Scientific meeting in Feb 2018



- High motivation from CHD KOLS to access ADAPT technology ASAP
- Regulatory process has commenced; potential commercial distribution partner engaged
- **Phase 1 - Invitro testing - completed Q2 2018**
- **Phase 2 – Clinical Trial**
 - Sites and KOLS selected; Protocol developed
 - Commence Q2 2018 - Complete Q2 2020
- Estimate market entry Q4 2020



Region Emerging Markets

Represents access to growing multi billion \$ market



- Market assessment in process
- Final recommendations due Q4 2017
 - Mexico and Columbia – commercial launch Q2 2018
 - Brazil - 2020
 - Argentina - 2019

PRIORITY TARGETS (2017-2020)

- LATAM
- AUS/ASIA PAC



Australia/NZ

- TGA approval in process – expected Q2 2018,
- Australian patients continue to access CardioCel via SAS program
- Starship Children's Hospital Auckland – CardioCel now approved

Asia Pacific

- Sales continue through Singapore, Malaysia, Hong Kong
- Regulatory approval pending: Taiwan, Vietnam, Thailand, Philippines (flow from TGA approval_
- Japan – regulatory assessment in process

Admedus Infusion



Key achievements

- Profitable business unit
- \$15.2 million in revenue = **74% growth**
- Growth being driven from key target products in portfolio
 - Arcomed
 - AMBIT
 - Springfusor
 - Vsets
- Increased penetration into private segment with AMBIT
- Secured Mercy Ascot (NZ), Gawler Health (SA), and Western Private (SA) for Arcomed system



New Royal Adelaide Hospital

- It's now 'live'
- Implementation project continues into Q3-Q4 2017
- ~2000 clinical staff trained
- ~ revenue forecast > \$1 million per annum
- Follow-on projects in SA Health
 - Several SA Public Hospitals looking to replace Infusion fleet 2017-2019
 - Will be viewing NRAH as a key reference point

Tech Ops FY17 by the numbers



- Annualized savings ~ \$1.0M on a \$4.3M mfg. site budget (23% VIP/VOP)
- Improve pass rate from 47% to 76%
- Improve tissue yield by ~ 60%
- Reduced electrical consumption & greenhouse gas emissions by 40%
- > 45% Reduction is COGS
- 0 regional stock-outs
- 0 critical audit findings



Tech Ops FY17 – New Capabilities



Developed and Implemented


- Cutting complex ADAPT® scaffold shapes
- 3D processing of ADAPT® scaffolds
- Thickness differentiation
- Bulk processing of pericardia in preparation of significant volume increase
- Validated processing larger size of 6cm x 14cm

Developing ... in Feasibility (planned late FY18 implementation)

- Control of ADAPT® scaffold thickness
 - ✓ First automated machine prototype complete
 - ✓ Processed a pericardium sheet from .5mm to .3mm
 - ✓ Processed a portion of a pericardium sheet as low as .15mm
 - ✓ Capability to produce two different thickness levels in same sheet


Immunotherapies

- Developing RNA vaccines as an expansion of the overall platform
- Collaboration with Translate Bio (formerly Rana, formerly Shire)
- Targeting immunoncology, specifically HPV related cancer
- Initial data showing strong in vitro immune responses
- Further updates through the coming year
- BOD reviewing funding options, both private and public routes under consideration




3D and the future of shaped collagen

- The variability of techniques and individual patients require AHZ to gather data on multiple use scenarios in a structured and responsible manner to ensure the best possible information is available for surgeons at launch
- Evaluation program underway – will be complete in calendar Q4
- Major centers in the US and AU compiling use case data
- Commercial launch calendar Q1 2018



TAVR – alive and well

- Multiple IP files ready to go within two weeks
- Utilization of 3D molding abilities applied to single piece valve
- Innovations in process involving the catheter
- Project on schedule



4C Medical supply agreement



TMVR market potential is very large

- **\$3B** Market by 2022, with **15.9%** CAGR
- 4.1 million patients in US and EU, 250,000 new patients annually
- High area of unmet need for patients unable to undergo mitral valve repair surgery



“novel minimally invasive solution for the treatment of mitral regurgitation”

Agreement Highlights

- Significant source of revenue
- Exclusive agreement to supply
- Offers patients with MR the transformative healing of ADAPT
- Sets the stage for co-development across the full transcatheter spectrum



BACKED BY

 **20**

YEARS OF SCIENCE

Two decades of peer-reviewed, published data provide strong evidence for ADAPT[®] technology¹⁻⁷



Through the eyes of the microscope, ADAPT[®] was verified as a paradigm shift in bioprosthetic tissue engineering.

-Leon Neethling, PhD, FACA

Evidence of clinical superiority



- Results have shown that CardioCel has zero DNA readings after our ADAPT Tissue Engineering process
- The analysis was done by ARGF Ltd who is accredited in the field of Biological Testing (Scope: DNA Analysis) according to the ISO 17025:2005 standard by the National Association of Testing Authorities (NATA)

Evidence of clinical superiority



1. Prabhu S, Armes JE, Bell D, et al. Histological evaluation of explanted tissue engineered bovine pericardium (CardioCel®). *Semin Thorac Cardiovasc Surg*. 2017. doi.org/10.1053/j.semtcvs.2017.05.017.
2. Brizard CP, Brink J, Horton SB, et al. New engineering treatment of bovine pericardium confers outstanding resistance to calcification in mitral and pulmonary implantations in a juvenile sheep model. *J Thorac Cardiovasc Surg*. 2014;148:3194-3201.
3. Neethling WM, Yadav S, Hodge A, Glancy R. Enhanced biostability and biocompatibility of decellularized bovine pericardium, crosslinked with an ultra-low concentration monomeric aldehyde and treated with ADAPT. *J Heart Valve Dis*. 2008;17:456-463; discussion 464.
4. Svendsen, CA, Kreykes NS, Butany J, Bianco RW. In-vivo assessment of a photofixed bovine pericardial valve. *J Heart Valve Dis*. 2000;9:813-820.
5. Neethling W, Glancy R, Hodge A. Mitigation of calcification and cytotoxicity of a glutaraldehyde-preserved bovine pericardial matrix: improved biocompatibility after extended implantation in the subcutaneous rat model. *J Heart Valve Dis*. 2010;19:778-785.
6. Neethling W, Brizard C, Firth L, Glancy R. Biostability, durability and calcification of cryopreserved human pericardium after rapid glutaraldehyde-stabilization versus multistep ADAPT® treatment in subcutaneous rat model. *Eur J Cardiothorac Surg*. 2014;45:e110-e117.
7. Carpentier S, Carpentier AF, Quintero LJ, Packham VS, Wang JH, Schreck SG, inventors; Edwards Lifescience Corporation, assignee. Apparatuses for treating biological tissue to mitigate calcification. US patent 6,210,957, April 3, 2001.
8. Neethling WM, Strange G, Firth L, Smit FE. Evaluation of a tissue-engineered bovine pericardial patch in paediatric patients with congenital cardiac anomalies: initial experience with the ADAPT-treated CardioCel® patch. *Interact Cardiovasc Thorac Surg*. 2013;17:698-702.
9. Long-term CardioCel study shows no evidence of calcification after 8 years [news release]. August 22, 2016. <http://www.admedus.com/wp-content/uploads/2016/08/152208A-Long-term-CardioCel-study-shows-no-evidence-of-calcification-after-8-years/>. Accessed June 4, 2017.
10. Data on file. Admedus.
1. Neethling WM, Yadav S, Hodge A, Glancy R. Enhanced biostability and biocompatibility of decellularized bovine pericardium, crosslinked with an ultra-low concentration monomeric aldehyde and treated with ADAPT. *J Heart Valve Dis*. 2008;17:456-463; discussion 464.
2. Brizard CP, Brink J, Horton SB, Edwards GA, Galati JC, Neethling WM. New engineering treatment of bovine pericardium confers outstanding resistance to calcification in mitral and pulmonary implantations in a juvenile sheep model. *J Thorac Cardiovasc Surg*. 2014;148:3194-3201.
3. Svendsen, CA, Kreykes NS, Butany J, Bianco RW. In-vivo assessment of a photofixed bovine pericardial valve. *J Heart Valve Dis*. 2000;9:813-820.
4. Neethling WM, Glancy R, Hodge AJ. Mitigation of calcification and cytotoxicity of a glutaraldehyde-preserved bovine pericardial matrix: improved biocompatibility after extended implantation in the subcutaneous rat model. *J Heart Valve Dis*. 2010;19:778-785.
5. Neethling W, Brizard C, Firth L, Glancy R. Biostability, durability and calcification of cryopreserved human pericardium after rapid glutaraldehyde-stabilization versus multistep ADAPT® treatment in subcutaneous rat model. *Eur J Cardiothorac Surg*. 2014;45:e110-e117.
1. Data on file. Admedus.
2. Huang HY, Balhouse BN, Huang S. Application of simple biomechanical and biochemical tests to heart valve leaflets: implications for heart valve characterization and tissue engineering. *Proc Inst Mech Eng H* 2012;226:868-876.
3. Kalejs M, Stradins P, Laciš R, Ozolanta I, Pavars J, Kasyanov V. St. Jude Epic heart valve bioprosthesis versus native human and porcine aortic valves—comparison of mechanical properties. *Interact Cardiovasc Thorac Surg*. 2009;8:553-556.
4. Zioupos P, Barbenel JC, Fisher J. Anisotropic elasticity and strength of glutaraldehyde fixed bovine pericardium for use in pericardial bioprosthetic valves. *J Biomed Mater Res*. 1994;28:49-57.

*A selection of footnoted proof points from a range of sources
(shown with some overlapping duplicates for formatting reasons)*

Evidence of clinical superiority



1. Neethling WM, Glancy R, Hodge AJ. ADAPT-treated porcine valve tissue (cusp and wall) versus Medtronic Freestyle and Prima Plus: crosslink stability and calcification behavior in the subcutaneous rat model. *J Heart Valve Dis.* 2004;13:689-696.
2. Neethling WM, Hodge AJ, Clode P, Glancy R. A multi-step approach in anti-calcification of glutaraldehyde-preserved bovine pericardium. *J Cardiovasc Surg (Torino).* 2006;47:711-718.
3. Neethling WM, Yadav S, Hodge A, Glancy R. Enhanced biostability and biocompatibility of decellularized bovine pericardium, crosslinked with an ultra-low concentration monomeric aldehyde and treated with ADAPT. *J Heart Valve Dis.* 2008;17:456-463; discussion 464.
4. Neethling WM, Glancy R, Hodge AJ. Mitigation of calcification and cytotoxicity of a glutaraldehyde-preserved bovine pericardial matrix: improved biocompatibility after extended implantation in the subcutaneous rat model. *J Heart Valve Dis.* 2010;19:778-785.
5. Neethling WM, Strange G, Firth L, Smit FE. Evaluation of a tissue-engineered bovine pericardial patch in paediatric patients with congenital cardiac anomalies: initial experience with the ADAPT-treated CardioCel[®] patch. *Interact Cardiovasc Thorac Surg.* 2013;17:698-702.
6. Neethling W, Brizard C, Firth L, Glancy R. Biostability, durability and calcification of cryopreserved human pericardium after rapid glutaraldehyde-stabilization versus multistep ADAPT[™] treatment in subcutaneous rat model. *Eur J Cardiothorac Surg.* 2014;45:e110-e117.
7. Strange G, Brizard C, Karl TR, Neethling L. An evaluation of Admedus' tissue engineering process-treated (ADAPT) bovine pericardium patch (CardioCel) for the repair of cardiac and vascular defects. *Expert Rev Med Devices.* 2014;1-7. doi: 10.1586/17434440.2015.985651.
8. Neethling WM, Strange G, Firth L, Smit FE. Evaluation of a tissue-engineered bovine pericardial patch in paediatric patients with congenital cardiac anomalies: initial experience with the ADAPT-treated CardioCel[®] patch. *Interact Cardiovasc Thorac Surg.* 2013;17:698-702.
9. Long-term CardioCel study shows no evidence of calcification after 8 years. Admedus. <http://www.admedus.com/wp-content/uploads/2016/08/162208A-Long-term-CardioCel-study-shows-no-evidence-of-calcification-after-8-years.pdf>. Updated August 22, 2016. Accessed June 4, 2017.
10. Svendsen CA, Kreykes NS, Butany J, Bianco RW. In-vivo assessment of a photofixed bovine pericardial valve. *J Heart Valve Dis.* 2000;9:813-820.
11. Peri-Guard[®] Instructions for use. Synovis Surgical Innovations, Inc. May 2011.
12. XenoSure[®] Biologic Patch Instructions for Use. LeMaitre Vascular, Inc. <https://eifu.lemaitre.com/ifu/archive/ARCHIVE%20R2390-00.Rev.A.08.13.pdf>. Updated August 2013. Accessed June 20, 2017.
13. LeMaitre Vascular - Product Models & Specifications. LeMaitre Vascular, Inc. http://lemaitre.com/specs_POP.ASP. Updated 2017. Accessed 6/27/2017.
14. SJM[™] Pericardial Patch With Encap[™] AC Technology: Product Highlights. St. Jude Medical, Inc. <https://www.sjmglobal.com/en-int/professionals/resources-and-reimbursement/technical-resources/structural-heart/valve-repair/pericardial-patch/sjm-pericardial-patch-with-encap-ac-technology>. Updated April 19, 2013. Accessed June 27, 2017.
15. Lee C, Hong-Gook L, Lee CH, et al. Effects of glutaraldehyde concentration and fixation time on material characteristics and calcification of bovine pericardium: implications for the optimal method of fixation of autologous pericardium used for cardiovascular surgery. *Interact Cardiovasc Thorac Surg.* 2017;24:402-406.
16. Synergraft Decellularized Technology. CryoLife, Inc. <http://www.cryolife.com/products/cardiac-allografts/synergraft-technology/>. Accessed June 27, 2017.
17. Muto A, Nishibe T, Dardik H, et al. Patches for carotid artery endarterectomy: current materials and prospects. *J Vasc Surg.* 2009;50:206-213. doi:10.1016/j.jvs.2009.01.062.
18. Rerkasem K, Rothwell P. Systematic review of randomized controlled trials of patch angioplasty versus primary closure and different types of patch materials during carotid endarterectomy. *Asian J Surg.* 2011;34:32-40.

A selection of footnoted proof points from a range of sources (shown with some overlapping duplicates for formatting reasons)

What's next ?

- Multiple announcements in the pipeline for calendar Q4
- IP files to be lodged on several TAVR innovations
- The launch of CardioCel 3D
- Introduction of new field force campaign materials in September
- First revenues from 4C Medical
- Expanded development of shaped collagen products
- Immunotherapies update



F17 Summary and Outlook



Substantial advances achieved on the turnaround agenda during the year, significantly re-setting the business through strong performance improvement whilst simultaneously driving transformative change

- Group revenues up 58%
- Group gross profit up 110%, driven by higher sales and margin expansion of 33%
- Group operating expenses down 25% and below F15 levels
- Group losses after tax down 50%
- Group operating cash outflows down 43%
- ADAPT®:
 - Sales up 30%, margins up 48% points driving gross profit up 368%
- Infusion
 - Sales up 74%, margins down 7% points driving gross profit up 48%
- As a result of operational and strategic improvements, Group expects to approach financial break even in last quarter of calendar year 2018 leading to profitability in the full calendar year 2019



Transform Their Futures

ONLY ADAPT®-PROCESSED BIOMATERIAL ALLOWS FOR TRANSFORMATIVE REPAIR WITH NATURAL HEALING



Native-cell integration, collagen synthesis, and neovascularization are the markers of transformative repair¹



No antigenic or immunogenic stimulus and no foreign-body reaction demonstrated²



No calcium-binding sites observed²⁻⁷



More than 8 years of proven clinical performance⁸⁻¹⁰



ADMEDUS

INNOVATIVE HEALTH SOLUTIONS



www.admedus.com

Follow us on    